Abstract The G1/S phase transition of the cell cycle, controlled by cyclin-dependent kinase 4/6 (CDK4/6), is frequently deregulated in metastatic prostate cancers, establishing a rationale for CDK4/6 inhibition as a therapeutic strategy. However, clinical trials in prostate cancer have shown limited efficacy due to resistance mechanisms that remain unclear.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Michelle
Contact Michelle, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack